Novartis’ Rhapsido safer than rivals, Phase 3 multiple sclerosis data suggestnews2026-09-01T11:30:44+00:00September 1st, 2026|Endpoints News|
ARCH Venture Partners targets $3 billion raise for latest fundnews2026-09-01T00:55:30+00:00September 1st, 2026|Endpoints News|
Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also pausednews2026-09-01T00:01:19+00:00September 1st, 2026|Endpoints News|
Trump announces nine new MFN drug pricing dealsnews2026-08-31T19:56:17+00:00August 31st, 2026|Endpoints News|
Take the Q3 Biopharma Sentiment Survey (BPSI)news2026-08-31T15:44:09+00:00August 31st, 2026|Endpoints News|
Sanofi-backed Electra files for IPO to fund Phase 2/3 immunology drugnews2026-08-31T14:28:28+00:00August 31st, 2026|Endpoints News|
Lilly to buy TED startup Merida Biosciences in its 13th acquisition of 2026news2026-08-31T13:47:00+00:00August 31st, 2026|Endpoints News|
#ESC26: Arrowhead claims safety edge over Ionis as triglyceride battle draws closernews2026-08-30T15:40:30+00:00August 30th, 2026|Endpoints News|
#ESC26: AstraZeneca’s relaxin pill shows promise in mid-stage heart failure trialnews2026-08-30T07:19:28+00:00August 30th, 2026|Endpoints News|
